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The 8th edition of the AJCC TNM staging system showes slightly improved, 
but still not perfect prognostication for esophageal carcinomas
treated by neoadjuvant therapy followed by surgery
The 8th edition of the UICC/AJCC TNM staging
system (TNM8) provides slight, but simplifying changes
compared to the preceding 7th edition (TNM7) In
addition, the AJCC presents for the first time a
specific staging system for esophageal carcinomas
treated with neoadjuvant therapy followed by
surgery. We compared the prognostic value of this
novel staging system of AJCC TNM8 with TNM7.
Histology work up The whole macroscopically 
detectable tumor bed was embedded. HE staining 
was performed for routine histopathological analysis. 
In cases without viable tumor in the first sections, 
additional deeper sections were performed. The ypT, 
ypN and M categories were recorded from the 
pathology files, or obtained from the original slides if 
the information in the original report was unclear 
Staging Tumor stage were classified according to 
TNM7 and TNM8. TNM7 staging was expanded by the 
additional introduction of a „stage 0“ in cases of 
ypT0N0M0 tumors which would have been reserved 
for ypTis tumors in the original staging systems. Cases 
with lymph node or distant metastases without 
evidence of residual cancer in the primary tumor site 
(i.e. ypT0N>0/M>0) were classified according to the 
lowest T category in the respective
The 8th edition of the AJCC TNM classification allows for the first time accurate staging esophageal carcinomas treated by neoadjuvant therapy. 
Prognostication has slightly improved as compared to the preceding TNM7, but still appears not perfect. 
Stage Distribution in TNM7 and TNM8: Complete regression of the primary tumor was 
observed in 50 cases (25.25%). The cases were included into stage I (ypT0N0M0; n=42), 
stage IIIA (ypT0N1M0; n=6) stage IVA (ypT0N3M0; n=1) and stage IVB (ypT0N0M1; n=1) in 
TNM8. Besides the 42 cases with complete regression of the primary tumor and without 
metastases, 24 cases of TNM7 stage IA and 20 cases of TNM7 stage IB tumors were 
incorporated into the newly defined yTNM8 stage I group. yTNM8 stage II is equal to 
TNM7 stage IIA, and yTNM8 stage IIIA is equal to TNM7 stage IIB. 
In yTNM8 stage IIIB there are tumors with TNM7 stage IIIA and IIIB now collapsed, meaning 
a simplification of stages but not literally a stage migration. 
TNM7
Stage pT pN pM
IA 1 0 0
IB 2 0 0
IIA 3 0 0
IIB 1, 2 1 0
IIIA 4a 0 0
3 1 0
1, 2 2 0
IIIB 3 2 0
IIIC 4a 1,2 0
4b Any 0
Any 3 0
IV Any Any 1
yTNM8
Stage ypT ypN ypM
I 0-2 0 0
II 3 0 0
IIIA 0-2 1 0
IIIB 0-3 2 0
3 1 0
4a 0 0
IVA Any 3 0
4a 1-2 0
4b Any 0
IVB Any Any 1
Patients: Out of 272 patients who consecutively 
underwent surgery due to esophageal malignancy 
between 2001 and 2016 in the Department of 
Visceral Surgery at the Inselspital Bern, we selected all 
198 cases with esophageal carcinomas (144 adeno; 
54 squamous cell carcinomas) treated with 
neoadjuvant radiochemotherapy (n= 147) or 
chemotherapy (n= 51). 
Treatment: Preoperative radiation was performed 
with at least 40Gy. Chemotherapy was 5-FU and 
Cisplatin/Carboplatin based. For surgery, a 
transmediastinal esophagectomy with a radical 
bilateral mediastinal en-bloc lymphadenectomy 
(TME) was performed in most cases. Mean number of 
resected lymph nodes was 26. In 180 cases, complete 
tumor resection was achieved. In 7 cases, no 
esophagectomy was performed (evidence of distant 
metastases during surgery), however, these cases 
were classified as stage IV (TNM7) or IVB (TNM8)
Survival Analysis Mean survival was 172 months (95%CI 45-300). There was no significant 
difference between adeno- and squamous cell carcinomas (p=0.71). Higher pT category 
(p<0.001), pN category (p<0.001), resection status (p=0.003)  and in trend presence of 
distant metastases (p=0.090) were associated with worse overall survival.
Tumor staging in TNM7 showed highly significant prognostic impact (p<0.001). However, 
stage IIB tumors (pT1/pT2N1) had better prognosis compared to stage IA (ypT1N0), IB 
(pT2N0) and IIA (pT3N0) tumors. For TNM8, a similar prognostic value was observed when 
using the novel proposed ypTNM classification (p<0.001), and, likewise stage IIIA tumors 
(ypT0-2N1) were better than stage II (ypT3N0)
yTNM8
Total
Stage I Stage II Stage IIIA Stage IIIB Stage IVA Stage IVB
„Stage 0“ 42 0 0 0 0 0 42
Stage IA 24 0 0 0 0 0 24
Stage IB 20 0 0 0 0 0 20
Stage IIA 0 21 0 0 0 0 21
TNM7 Stage IIB 0 0 24 0 0 0 24
Stage IIIA 0 0 0 27 0 0 27
Stage IIIB 0 0 0 13 0 0 13
Stage IIIC 0 0 0 0 11 0 11
Stage IV 0 0 0 0 0 16 16
Total 86 21 24 40 11 16 198
Comparison of TNM7 and yTNM8 Using AIC and SBC as parameters for goodness-of-fit, 
TNM8 was slightly superior regarding prognostication (TNM7 AIC=1593.239; 
SBC=1619.088; TNM8 AIC=1589.331; SBC=1605.487: lower values of AIC and SBC 
indicate superior model fit with the “better” model showing the lowest values for both). 
A simplified staging with collapsed stages (i.e. stages IIA and IIB collapsed to stage II) 
did not improve AIC or SBC values. Similar results were seen for adenocarcinomas and 
squamous cell carcinomas if analyzed separately
